^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    M701

    i
    Other names: M701
    Associations

    News

    Trials
    Company:
    Sino Biopharm, YZY Biopharma
    Drug class:
    CD3 agonist, EPCAM inhibitor
    Related drugs:
    Associations

    News

    Trials
    4ms
    A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC (clinicaltrials.gov)
    P1/2, N=96, Recruiting, Wuhan YZY Biopharma Co., Ltd. | Not yet recruiting --> Recruiting | Trial completion date: Dec 2024 --> Oct 2026 | Trial primary completion date: Jun 2024 --> Apr 2026
    Enrollment open • Trial completion date • Trial primary completion date
    |
    cisplatin • M701
    4ms
    Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody (clinicaltrials.gov)
    P3, N=312, Active, not recruiting, Wuhan YZY Biopharma Co., Ltd. | Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2025 --> Nov 2025
    Enrollment closed • Trial primary completion date
    |
    M701
    4ms
    Treat Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer With M701 Bispecific Antibody (clinicaltrials.gov)
    P2, N=115, Completed, Wuhan YZY Biopharma Co., Ltd. | Active, not recruiting --> Completed | N=80 --> 115 | Trial completion date: Dec 2024 --> Aug 2024
    Trial completion • Enrollment change • Trial completion date
    |
    M701
    5ms
    A Study of M701 (EpCAM and CD3) in Malignant Ascites (clinicaltrials.gov)
    P1, N=35, Completed, Wuhan YZY Biopharma Co., Ltd. | Recruiting --> Completed
    Trial completion
    |
    CA 19-9 (Cancer antigen 19-9)
    |
    M701
    over1year
    Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody (clinicaltrials.gov)
    P3, N=270, Recruiting, Wuhan YZY Biopharma Co., Ltd.
    New P3 trial • Metastases
    |
    EPCAM (Epithelial cell adhesion molecule)
    |
    M701
    almost2years
    Treat Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer With M701 Bispecific Antibody (clinicaltrials.gov)
    P2, N=80, Active, not recruiting, Wuhan YZY Biopharma Co., Ltd.
    New P2 trial
    |
    M701
    3years
    A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC (clinicaltrials.gov)
    P1/2, N=96, Not yet recruiting, Wuhan YZY Biopharma Co., Ltd.
    New P1/2 trial
    |
    EPCAM (Epithelial cell adhesion molecule)
    |
    EPCAM expression
    |
    cisplatin • M701